When it is eventually completed – and the anticipated date for clearance from EU regulators is early November – the GN-Amplifon transaction will be, saving some new revelation, the hearing market’s biggest story of the decade. PW/Open AI One of the oldest names in the hearing-aid business is effectively selling its hearing identity to the world’s largest independent hearing-care retailer....
Continue reading at Audiology Worldnews
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is financial and business news with no direct implications for clinical practice.
The potential GN-Amplifon merger could reshape the competitive landscape of hearing aid distribution and retail across Europe and beyond, with downstream effects on pricing, product access, and independent clinic viability.
- 01H1 2024 financial reports from major hearing-aid manufacturers signal a healthy and growing market.
- 02GN and Amplifon are pursuing a transaction described as potentially the largest deal in the hearing market this decade.
- 03EU regulatory clearance for the GN-Amplifon deal is expected in early November.
- 04Vertical integration of a manufacturer (GN) with a large retail chain (Amplifon) raises competition questions.
- 05The outcome of EU review could set precedent for further consolidation in hearing care.
The GN-Amplifon transaction is potentially the hearing market's largest deal of the decade.
opinionunclearEU regulatory clearance for the GN-Amplifon deal is expected in early November.
press releasepartially supportedH1 financial reports from hearing-aid manufacturers indicate the hearing market is performing well.
studysupported
